Literature DB >> 18097045

TLR9 contributes to antiviral immunity during gammaherpesvirus infection.

Simone Guggemoos1, Doris Hangel, Svetlana Hamm, Antje Heit, Stefan Bauer, Heiko Adler.   

Abstract

The human gammaherpesviruses Kaposi's sarcoma-associated herpesvirus and EBV cause important infections. As pathogenetic studies of the human infections are restricted, murine gammaherpesvirus 68 serves as a model to study gammaherpesvirus pathogenesis. TLRs are a conserved family of receptors detecting microbial molecular patterns. Among the TLRs, TLR9 recognizes unmethylated CpG DNA motifs present in bacterial and viral DNA. The aim of this study was to assess the role of TLR9 in gammaherpesvirus pathogenesis. Upon stimulation with murine gammaherpesvirus 68, Flt3L-cultured bone marrow cells (dendritic cells) from TLR9-/- mice secreted reduced levels of IL-12, IFN-alpha, and IL-6, when compared with dendritic cells from wild-type mice. Intranasal infection of TLR9-/- and wild-type mice did not reveal any differences during lytic and latent infection. In contrast, when infected i.p., TLR9-/- mice showed markedly higher viral loads both during lytic and latent infection. Thus, we show for the first time that TLR9 is involved in gammaherpesvirus pathogenesis and contributes to organ-specific immunity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18097045     DOI: 10.4049/jimmunol.180.1.438

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

Review 1.  Recent insights into the role of Toll-like receptors in viral infection.

Authors:  M Carty; A G Bowie
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

Review 2.  Recognition of herpesviruses by the innate immune system.

Authors:  Søren R Paludan; Andrew G Bowie; Kristy A Horan; Katherine A Fitzgerald
Journal:  Nat Rev Immunol       Date:  2011-02       Impact factor: 53.106

3.  R753Q polymorphism inhibits Toll-like receptor (TLR) 2 tyrosine phosphorylation, dimerization with TLR6, and recruitment of myeloid differentiation primary response protein 88.

Authors:  Yanbao Xiong; Chang Song; Greg A Snyder; Eric J Sundberg; Andrei E Medvedev
Journal:  J Biol Chem       Date:  2012-09-19       Impact factor: 5.157

4.  Murine gammaherpesvirus 68 infection protects lupus-prone mice from the development of autoimmunity.

Authors:  Jennifer D Larson; Joshua M Thurman; Anatoly V Rubtsov; David Claypool; Philippa Marrack; Linda F van Dyk; Raul M Torres; Roberta Pelanda
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-02       Impact factor: 11.205

5.  Induction of necroptotic cell death by viral activation of the RIG-I or STING pathway.

Authors:  Suruchi N Schock; Neha V Chandra; Yuefang Sun; Takashi Irie; Yoshinori Kitagawa; Bin Gotoh; Laurent Coscoy; Astar Winoto
Journal:  Cell Death Differ       Date:  2017-01-06       Impact factor: 15.828

6.  Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice.

Authors:  Edward M Behrens; Scott W Canna; Katharine Slade; Sheila Rao; Portia A Kreiger; Michele Paessler; Taku Kambayashi; Gary A Koretzky
Journal:  J Clin Invest       Date:  2011-05-16       Impact factor: 14.808

7.  Toll-like receptor agonists synergistically increase proliferation and activation of B cells by epstein-barr virus.

Authors:  Stefanie Iskra; Markus Kalla; Henri-Jacques Delecluse; Wolfgang Hammerschmidt; Andreas Moosmann
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

8.  Retention of anergy and inhibition of antibody responses during acute γ herpesvirus 68 infection.

Authors:  Andrew Getahun; Mia J Smith; Igor Kogut; Linda F van Dyk; John C Cambier
Journal:  J Immunol       Date:  2012-08-17       Impact factor: 5.422

9.  Involvement of TLR2 in recognition of acute gammaherpesvirus-68 infection.

Authors:  François Michaud; François Coulombe; Eric Gaudreault; Jasna Kriz; Jean Gosselin
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

Review 10.  Toll-like receptor polymorphisms, inflammatory and infectious diseases, allergies, and cancer.

Authors:  Andrei E Medvedev
Journal:  J Interferon Cytokine Res       Date:  2013-05-15       Impact factor: 2.607

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.